

JAN 30 2002

PATENT & TRADEMARK OFFICE

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Application Number	09/869169
--------------------	-----------

Filing Date	06/22/2001
-------------	------------

First Named Inventor	Paulussen
----------------------	-----------

Group Art Unit

Examiner Name

Attorney Docket Number	JAB-1462
------------------------	----------

er. **FIVE**

FEB 05 2002

LENIER 1600/2

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]


Examiner Signature	<i>[Signature]</i>	Date Considered	7/15/04
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
All information required by this form must be provided to the Office in a collection of information unless it displays a valid OMB control number.

Application Number	09/869169
Filing Date	06/22/2001
First Named Inventor	Paulussen
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1462

RECEIVED
FEB 05 2002
FEB 16 2002


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
[Signature]	1	Aoyama, T., et al., "Cytochrome P450 hPCN3 a novel cytochrome P450IIIA gene product that is differentially expressed in adult human liver", J.Biol. Chem. 1989 264:10388-10395	
	2	Barwick J.L., et al., "Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes" Molecular Pharmacology, 1996 50:10-16	
	3	Boobis A.R., et al., "Dissecting the function of cytochrome P450" Br. J. Clin. Pharmacol. 1996 42:81-89	
	4	Cholerton, S., et al., "The role of individual human cytochrome P450 in drug metabolism and clinical response" Trend Pharmac. Sci. 1992 13:434-439	
	5	Fujii-Kuriyama, et al., "Regulation of CYP1A1 expression" FASEB J. 1002 6:706-710	
	6	Gorski, J.C., et al., "Regioselective biotransformation of midazolam by members of the human cytochrome P450 (CYP3A) subfamily", Biochem. Pharmacol. 1994 9:1643-1653	
	7	Guengerich, F.P. "Characterisation of human cytochrome P450 enzymes", FASEB 1992 6:745-748	
	8	Hashimoto, H., et al. "Gene structure of CYP3A4, an adult specific form of cytochrome P450 in human livers and its transcriptional control", Eur. J. Biochem. 1993 218:585-595	
	9	Haehner, B.D. et al. "Bimodal distribution of renal cytochrome P450 3A activity in humans", Mol. Pharmacol., 1996 50:52-59	
	10	Hoffman, E.C., et al. "Cloning of a factor required for activity of the Ah (dioxin) receptor", Science, 1991 252:954-958	
	11	Hoyo-Vadillo, C. et al. "Pharmacokinetics of nifedipine slow release tablets in Mexican subjects: further evidence for an oxidative polymorphism", J. Clin. Pharmac. 1989 29:816-820	
	12	Imataka, H., et al., "Cell specific translational control of transcription factor BTEB expression. The role of an upstream AUG in the 5' untranslated region", J. Biol. Chem. 1994 269:20668-73	
	13	Itoh, S., et al. "Genomic organization of human fetal specific P-450IIIA7 (cytochrome P-450HFLA)- related gene(s) and interaction of transcriptional regulatory factor with its DNA element in the 5' flanking region", Biochimica et Biophysica Acta. 1992 1130:133-138	
[Signature]	14	Jounaidi, Y., et al., "Sequence of the 5'-flanking region of CYP3A5 comparative analysis with CYP3A4 and CYP3A7", Biochem. Biophys. Res. Commun. 1994 205: 1741-1747	

Examiner Signature	[Signature]	Date Considered	7/15/04
--------------------	-------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449/APTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 4

Application Number	09/869169
Filing Date	06/22/2001
First Named Inventor	Paulussen
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1462

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
[Signature]	15	Kormori M. et al. "Fetus specific expression of a form of cytochrome P-450 in human livers", Biochemistry 1990 29:4430-4433	
	16	Lavrijsen K., et al. "Induction potential of antifungals containing an imidazole or triazole moiety. Miconazole and ketoconazole, but not itraconazole are able to induce hepatic drug metabolising enzymes of male rats at high doses", Biochem. Pharmacol. 1986 35:1867-78	
	17	Miller, G.L. "Protein determination for large numbers of samples", Anal. Chem. 1959 31:964	
	18	Nebert, D.W. The Ah locus: genetic differences in toxicity, Cancer, mutation and birth defects. Critical Reviews in Toxicology, 20, 153-174 (1989).	
	19	Renwick, A.G., et al., "The pharmacokinetics of oral nifedipine - a population study", Br. J. Clin. Pharmacol. 1988 25:701-708	
	20	Schellens, J.H.M., et al., "Lack of bimodality nifedipine plasma kinetics in a large population of healthy subjects", Biochem. Pharmacol. 1988 37:2507-2510	
	21	Schuetz, J., et al., "Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver", Pharmacogenetics, 1994 4:11-20	
	22	Shimada, T., et al., "Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver", Proc. Natl. Acad. Sci. USA 1989 86:462-465	
	23	Sogawa, K., et al., "Comparison of DNA-binding properties between BTEB and Spl(1)". J. Biochem, 1993 114:605-9	
	24	Watkins, P.B. "Drug metabolism by cytochromes P450 in the liver and small bowel", Gastroenterology Clinics of North America, 1992 21:511-526	
	25	Wrighton, S.A. et al. "Studies in the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLP3)". Mol. Pharmacol. 1990 38:207-213	
	26	Rannug, A., et al. "Genetic Polymorphism of Cytochromes P450 1A1, 2D6 and 2E1: Regulation and Toxicological Significance", JOEM 37(1) 1995 pp. 25-36	
	27	Jounaidi, Y., et al. "Detection of a CYP3A5 Allelic Variant: A Candidate for the Polymorphic Expression of the Protein?" Biochemical and Biophysical Research Communication 1996 221:466-470	
	28	Meyer, Urs, et al. "Molecular Mechanisms of Genetic Polymorphisms of drug metabolism", Annual Rev. Pharmacol. Toxicol, 1997, 37:269-96	
	29	Paulussen, Aimee, et al. "Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans", Pharmacogenetics, 2000 10:415-425	
	30	Chou, Fang-Chun, et al. "Genetic polymorphism of cytochrome P450 3A5 in Chinese", DMD 2001 29:1205-1209,	
	31	Kuehl, P., et al. "Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression", Nature Genetics 2001 27:383-391	


Examiner Signature	[Signature]	Date Considered	7/15/04
--------------------	-------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Sheet 4 of 4

Application Number	09/869,169
Filing Date	06/22/2001
First Named Inventor	Paulussen
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1462

RECEIVED
FEB 05 2002
TECH CENTER 1500/2900

[illegible]

Examiner
Signature

Date _____

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.